(Q44128414)

English

Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel

scientific article published in September 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel (English)

1 reference

Europe PubMed Central

30 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Mark A Socinski

1

1 reference

Europe PubMed Central

30 November 2017

Michael J Schell

2

1 reference

Europe PubMed Central

30 November 2017

Kamal Bakri

3

1 reference

Europe PubMed Central

30 November 2017

Amy Peterman

4

1 reference

Europe PubMed Central

30 November 2017

Ji-Hyun Lee

5

1 reference

Europe PubMed Central

30 November 2017

Paul Unger

6

1 reference

Europe PubMed Central

30 November 2017

Steven Yates

7

1 reference

Europe PubMed Central

30 November 2017

Stacie Hudgens

8

1 reference

Europe PubMed Central

30 November 2017

Merrill S Kies

9

1 reference

Europe PubMed Central

30 November 2017

language of work or name

0 references

publication date

1 September 2002

1 reference

Europe PubMed Central

30 November 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

30 November 2017

95

1 reference

Europe PubMed Central

30 November 2017

6

1 reference

Europe PubMed Central

30 November 2017

1265-1273

1 reference

Europe PubMed Central

30 November 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Weekly paclitaxel in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

21 January 2018

Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10835

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10835

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44128414&oldid=2106885030"